Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Britain Courts Anthropic Amid US Defense Department Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Newark, NJ, June 19, 2017 -- Sanjeev Luther, Chief Operating Officer of Rafael Pharmaceuticals, Inc. (formerly Cornerstone Pharmaceuticals, Inc.), will present the company’s clinical development strategy as Rafael prepares for its upcoming pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML). Mr. Luther will also provide an overview of Rafael’s Altered Energy Metabolism Directed (AEMD) drug platform and the promising results from phase I trials of the company’s lead metabolic cancer drug, CPI-613.
Interviews with Mr. Luther are available upon request.
WHERE: Theater 2; San Diego Convention Center; 111 W Harbor Dr., San Diego, CA 92101
WHEN: June 21, 2017, 4:00 PM
CONTACT: Jacob Jonas, 973-438-3176 or [email protected]
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit http://www.rafaelpharma.com/.
